Returning in 2020 as part of the Microbiome Movement Drug Development Summit in Boston.
The Microbiome Movement – Oncology Response Summit 2019 was dedicated to harnessing and translating the microbiome to improve identification of patient responders, optimize cancer therapeutic strategies and ultimately enhance clinical outcomes.
Cancer drug development pipelines are driven forward by our well-established mechanistic knowledge of the hallmarks of cancer. However, challenges remain in pinpointing the impact of microbial dysbiosis in cancer therapeutic efficacy and safety, as well as its role in carcinogenesis. Additionally, there are shortfalls in understanding how the microbiome can be applied as a validated biomarker, monotherapy or adjuvant to enhance clinical outcomes for cancer patients in need.
The 2019 summit brought together large pharma, biotech companies, research institutes and technology experts in microbiome-oncology research to discuss the latest data-driven case studies and forge meaningful collaborations to maximize the potential of the microbiome as the next frontier that optimizes cancer therapeutic strategies for improved safety and efficacy.
This summit will return in 2020 as part of Microbiome Movement - Drug Development in Boston - register your interest here